Home | About Us | Grants | Resources | News & Events | Community

Vision: We may not be there yet, but we are closer than we were yesterday.


About Us
arrowHistory & Background

arrowGrant Opportunities
arrowGrant Process
arrowASN Co-Grants
arrow2015 Grant Recipient
2013 Grant Recipient
arrowTranslational Research

arrowPatient Registries
arrowMedical Experts
arrowBio Banks

News & Events
arrow2018 MN Conference in Bergamo
HFE Gene Linked to MN
arrowCureGN Study at Columbia
Protein Linked to Kidney Failure
NIH Renews NEPTUNE Funding
Childhood Stress not trigger for MS
arrowLevin succeeds Remuzzi at ISN

arrowSalant receives Hamburger Award
arrowDrug for MS & Alzheimer's
arrowNeurons & Salt
arrowAutoimmune-Allergy Connection
arrowA Cause of Recurrent MN
arrowBlood Test Detects Kidney Rejection
Genotyping of Risk Alleles
arrowLink to Gene Variants

arrowBlood Test to Detect MN
arrowMN, an Autoimmune Disease
arrowKey Molecule Impacts Mice
arrowLa Jolla Institute
arrowGluten Specific T-cells
arrowHuman Gene Pool
arrowVitamin D & Clinical Outcomes
arrowBovine Serum Albumen
Variations in HLA-DQA1 & PLA2R1 regions
arrowKlotho and Kidney Disease
arrowLink between MN and Milk (NEJM)

arrowASN News Release
arrowMario Negri News Release

arrowHyper-IgG4 Syndrome News Release
arrowAdvances in Kidney Disease (RSS)
arrowKidney Disease News (RSS)
arrowNew Patents (RSS)
arrowScience Daily (RSS)
arrowUpcoming Events
arrowEvents Archive

arrowPublic Service Announcement


Second Protein Associated with Common Cause of Kidney Failure Identified

17 November 2014 -- An international team of researchers including Jon Klein, M.D., Ph.D., and Michael Merchant, Ph.D., of the University of Louisville has identified a protein that turns a person’s immune system against itself in a form of kidney disease called membranous nephropathy (MN). The findings are published online in the New England Journal of Medicine.

This is the second protein associated with MN and the development of an autoimmune response.

Through the identification of this second protein, a new blood test can be developed to diagnose this common form of kidney disease.

Unchecked, MN can lead to kidney failure, or end stage renal disease. In 2011, more than a million people worldwide suffered from kidney failure annually, with more than 570,000 in the United States. Approximately 14 percent of those cases are the result of glomerulonephritis of which MN is a common cause.

“Five years ago this team initially discovered a protein that has led to a blood test identifying between 70 and 80 percent of people with MN,” said Klein, vice dean of research at UofL’s School of Medicine. “We now have found another protein that impacts up to another 5 percent of patients with MN. Once a blood test is available, we will have been able to reduce the number of kidney biopsies necessary for disease detection and to assess the response to treatment by up to 85 percent.”

Membranous nephropathy occurs when the small blood vessels in the kidney that filter wastes from the blood become inflamed and thickened. As a result, proteins leak from the damaged blood vessels into the urine. For many people, loss of these proteins eventually causes signs and symptoms known as nephrotic syndrome.

In 2009, Klein and this team reported the discovery that antibodies to kidney expression of phospholipase A2 receptor 1 (PLA2R1), were diagnostic for MN. That work, also reported in the New England Journal of Medicine, led to an FDA-approved test to diagnose MN. The PLA2R1 antibody test is positive in 80 percent of patients with MN. This week’s disclosure is related to the protein THSD7A. Researchers examined the blood of people known to have MN. Of the 154 people studied, 15 had antibodies to THSD7A, but not PLA2R1.

“This is significant because it provides us with another marker of identification and enables us to lessen the physical burden on our patients and ultimately will decrease the need for kidney biopsy. These MN antibody tests also allow us to monitor disease activity without kidney biopsy as we treat the patient. This allows a more rapid approach to developing new therapies for MN,” Klein said.

As pointed out by senior author Gérard Lambeau, Ph.D., director of research at Centre National de la Recherche Scientifique and Université de Nice Sophia Antipolis, Valbonne and team leader at the Institute of Molecular and Cellular Pharmacology (Sophia Antipolis), “This week’s disclosure is related to the discovery of the protein THSD7A and the corresponding anti-THSD7A autoantibodies in a group of about 10 percent of MN patients who did not have anti-PLA2R1 autoantibodies.”

“The discovery of this second antigen-antibody system in membranous nephropathy will allow clinicians to diagnose this new form of primary (autoimmune) membranous nephropathy and provides a new method to monitor the disease activity in this subgroup of patients,” said co-lead authors Nicola Tomas, M.D. of University Medical Center Hamburg–Eppendorf and Laurence Beck, M.D., Ph.D., of Boston University School of Medicine.

Catherine Meyer-Schwesinger, M.D., Barbara Seitz-Polski, M.D., Hong Ma, Ph.D., Gunther Zahner, Ph.D., Guillaume Dolla, M.S., Elion Hoxha, M.D., Udo Helmchen, M.D., Anne-Sophie Dabert-Gay, Ph.D., Delphine Debayle, Ph.D., David J. Salant, M.D., and Rolf A.K. Stahl, M.D., are part of the research team.

Source: University of Louisville
Special thanks to New England Journal of Medicine